<DOC>
	<DOCNO>NCT02714036</DOCNO>
	<brief_summary>This multi-center , open-label study MN-166 ( ibudilast ) subject ALS . To eligible subject must meet El Escorial criterion possible , laboratory-supported probable , probable , definite criterion diagnosis ALS . Safety , tolerability , blood , neuro-imaging biomarkers , clinical outcome collect subject . Subjects receive study drug 36 week . The study consist Screening Phase ( 6 week ) , Open-Label Treatment Phase ( 36 week ) Off-Treatment Follow-up Phase ( 4 Weeks ) . Number Subjects ( Planned ) : Approximately 35 subject plan screen goal enrol 25 subject .</brief_summary>
	<brief_title>A Biomarker Study Evaluate MN-166 ( Ibudilast ) Subjects With Amyotrophic Literal Sclerosis ( ALS )</brief_title>
	<detailed_description>This multi-center , open-label study MN-166 ( ibudilast ) subject ALS . To eligible subject must meet El Escorial criterion possible , laboratory-supported probable , probable , definite criterion diagnosis ALS . Safety , tolerability , blood , neuro-imaging biomarkers , clinical outcome collect subject . Subjects receive study drug 36 week . The study consist Screening Phase ( 6 week ) , Open-Label Treatment Phase ( 36 week ) Off-Treatment Follow-up Phase ( 4 Weeks ) . During Screening Phase , eligible ALS subject sign inform consent form follow screen assessment perform : review inclusion/exclusion criterion : El Escorial ALS Diagnostic criterion , medical history demographic , ALS diagnosis history , physical neurological examination , U. Penn upper motor Neuron Burden ( UMNB ) , pulmonary function test , vital sign include height weight , blood safety labs include TSPO affinity test , ECG review documentation concomitant medication therapy . Screening Phase ( 6 week ) The Treatment Phase consist Baseline visit 3 subsequent clinic visit Weeks 4 , 12 , 24 , 36 . Telephone follow-ups occur Weeks 1 , 2 , 8 , 16 , 20 , 28 , 32 . Open-Label Treatment Phase ( 36 week ) At Baseline visit , subject return clinic follow assessment performed/administered : review inclusion exclusion criterion continue eligibility , vital sign , blood safety lab biomarkers , ECG , ALSFRS-R questionnaire , slow vital capacity ( SVC ) , baseline strength measure hand hold dynamometry ( HHD ) , Columbia Suicide Severity Rating Scale ( C-SSRS ) . At visit , study drug dispense , adverse event , concomitant medication therapy assess document . At subsequent visit Treatment Phase , similar assessment perform . In addition , [ 11C ] PBR28-PET scan perform Screening Baseline visit , Week 20 Week 28 phone call . The ALSFRS-R , SVC U Penn Upper Motor Neuron Burden repeat day PET scan . The follow-up visit consist telephone call document adverse event concomitant therapy</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Ibudilast</mesh_term>
	<criteria>1 . Subjects must diagnose possible , probable , probablelaboratory support , definite ALS , either sporadic familial accord modify El Escorial criterion . 2 . Age 18 , able provide inform consent , safely comply study procedure . 3 . Vital capacity ( VC ) least 50 % predict value gender , height age screen visit , opinion study physician , able safely tolerate study procedure . ( Not applicable flexible arm ) 4 . Subject must able swallow oral medication Baseline Visit expect able swallow capsule throughout course study . 5 . Subject must take riluzole least 30 day , stable dose riluzole least 30 day , prior screening ( riluzolenaïve participant permit study ) . ( Not applicable flexible arm ) 6 . Women must able become pregnant ( e.g . post menopausal , surgically sterile , use adequate birth control ) duration study 3 month study completion . 7 . Males practice contraception duration study 3 month completion . 8 . Ability safely lie flat 90 min PET procedure opinion study physician . ( Not applicable flexible arm ) 9 . High mixed affinity bind TSPO protein ( Ala/Ala Ala/Thr ) ( see section 7.2.1 ) . ( Not applicable flexible arm ) 10 . Upper motor Neuron Burden ( UMNB ) Score ≥25 ( 45 ) screen visit . ( Not applicable flexible arm ) 1 . Abnormal liver function define AST and/or ALT &gt; 3 time upper limit normal . 2 . Renal insufficiency define serum creatinine &gt; 1.5 time upper limit normal . 3 . The presence unstable psychiatric disease , cognitive impairment , dementia would impair ability participant provide inform consent , accord PI judgment . 4 . Clinically significant unstable medical condition ( ALS ) would pose risk participant participate study . 5 . History HIV , clinically significant chronic hepatitis , active infection . 6 . Active inflammatory condition autoimmune disorder ( Not applicable flexible arm ) 7 . Females must lactate pregnant . 8 . Active participation another ALS clinical trial exposure label ALS experimental treatment within 30 day Baseline Visit ( Not applicable flexible arm ) 9 . Exposure immunomodulatory medication within 30 day Baseline Visit . ( Not applicable flexible arm ) 10 . Any contraindication undergo MRI study History cardiac pacemaker pacemaker wire Metallic particle body Vascular clip head Prosthetic heart valve Claustrophobia ( Not applicable flexible arm ) 11 . Radiation exposure exceed site 's current guideline ( Not applicable flexible arm ) 12 . Current use tobacco product include cigarette , cigar , snuff chew tobacco , nicotine replacement product gum patch ( Not applicable flexible arm ) 13 . EKG find QTc prolongation &gt; 450 m male &gt; 470 m female screen baseline . 14 . Not prohibitive medication know QT prolong medication :</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ALS</keyword>
</DOC>